Immunology/Inflammation

Immunology/Inflammation(免疫及炎症)

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

研究方向

Immunology/Inflammation 相关产品(4245)

  • GC73311 structure
    GC73311STAT3-IN-13
    CAS: 2248552-86-3
    纯度: >99.00%

    STAT3-IN-13(化合物6f)是一种有效的STAT3抑制剂。

  • GC73313 structure
    GC73313PI3Kα-IN-9
    CAS: 2715287-67-3
    纯度: >99.00%

    PI3Kα-IN-9(化合物27)是一种选择性、长效和口服活性的PI3Kα抑制剂,对PI3Kα、PI3Kγ、PI3Kδ和PI3Kβ的IC50值分别为4.4、128、146和153 nM。

  • GC73317 structure
    GC73317ODN 1585 sodium
    纯度: >93.00%

    ODN 1585 sodium是IFN和TNFα产生的强效诱导剂。

  • GC73318 structure
    GC73318ODN 2007 sodium
    纯度: >99.50%

    ODN 2007 sodium是B类CpG ODN (oligodeoxynucleotide),是toll样受体(Toll-like receptor, TLR)配体。

  • GC73319 structure
    GC73319FITC-labeled ODN 2216 sodium
    纯度: >97.00%

    FITC-labeled ODN 2216 sodium是人类特异性TLR9 toll样受体9配体或激动剂。

  • GC73320 structure
    GC73320ODN 2216 sodium
    纯度: >97.00%

    ODN 2216 sodium是人类特异性TLR9(toll样受体9)配体或激动剂。

  • GC73321 structure
    GC73321ODN 2336 sodium
    纯度: >90.00%

    ODN 2336 sodium是一种a类CpG ODN(寡脱氧核苷酸),是一种强效的TLR9激动剂。

  • GC73322 structure
    GC73322ODN 24888 sodium
    纯度: >93.00%

    ODN 24888 sodium是鸟嘌呤修饰的抑制性寡核苷酸(INH-ODN)。

  • GC73323 structure
    GC73323ODN 24987 sodium
    纯度: >92.00%

    ODN 24987 sodium是一种鸟嘌呤修饰的抑制寡核苷酸(ODN),靶向TLR9。

  • GC73324 structure
    GC73324ODN 24991 sodium
    纯度: >96.00%

    ODN 24991 sodium鸟嘌呤修饰的抑制性寡核苷酸(INH-ODN)是一种TLR3、TLR7和TLR9(Toll样受体)抑制剂,其亲本是INH-ODN2088。

  • GC73325 structure
    GC73325ODN D-SL01 sodium
    纯度: >99.00%

    ODN D-SL01 sodium是B类CpG ODN (oligodeoxynucleotide),是一种TLR9激动剂。

  • GC73326 structure
    GC73326ODN D-SL03 sodium
    纯度: >99.00%

    ODN D-SL03 sodium是C类CpG寡核苷酸,可诱导刺激pbmc产生高水平的IFN-α。

  • GC73327 structure
    GC73327ODN M362 sodium
    纯度: >93.00%

    ODN M362 sodiumC类寡脱氧核苷酸是TLR-9激动剂,可用作疫苗佐剂。

  • GC73328 structure
    GC73328ODN TTAGGG sodium
    纯度: >99.00%

    ODN TTAGGG sodium,抑制性寡核苷酸(ODN),是一种TLR9, AIM2和cGAS拮抗剂。

  • GC73355 structure
    GC73355STAT3-SH2 domain inhibitor 1
    CAS: 2816059-41-1
    纯度: >98.50%

    STAT3-SH2 domain inhibitor 1是STAT3(STAT3-SH2结构域)的强效Src同源2(SH2)结构域抑制剂,Kd值为1.57μM。

  • GC73371 structure
    GC73371Enpp/Carbonic anhydrase-IN-2
    CAS: 2883495-39-2
    纯度: >99.00%

    Enpp/Carbonic anhydrase-IN-2是一种强效的Enpp和碳酸酐酶抑制剂,NPP1、NPP2、NPP3、CA-IX、CA-XII的IC50分别为1.13、1.07、0.74、0.33、0.68。

  • GC73396 structure
    GC73396PRMT6-IN-3
    CAS: 2890765-10-1
    纯度: >99.00%

    PRMT6-IN-3(化合物25)是一种选择性PRMT6抑制剂,IC50值为192 nM。

  • GC73407 structure
    GC73407STING agonist-26
    CAS: 2868261-48-5
    纯度: >99.00%

    STING agonist-26 (CF508)是一种非核苷酸小分子STING激动剂。

  • GC73413 structure
    GC73413ARC186 sodium
    纯度: >94.00%

    ARC186 sodium是一种未偶联的40KDa PEG适体,其序列与0 Avacincaptad pegol ARC1905钠相同。

  • GC73417 structure
    GC73417CASP8-IN-1
    CAS: 1956368-39-0
    纯度: >98.00%

    CASP8-IN-1(化合物63-R)是胱天蛋白酶8(CASP8)的选择性抑制剂,IC50为0.7μM。

  • GC73424 structure
    GC73424PRT062607 acetate
    CAS: 1370261-98-5
    纯度: >99.00%

    PRT062607 acetate是一种口服Syk抑制剂(IC50: 1 nM),可抑制炎症和诱导细胞凋亡。

  • GC73428 structure
    GC73428CWI1-2 hydrochloride
    CAS: 2408590-37-2
    纯度: >98.00%

    CWI1-2 hydrochloride是一种结合IGF2BP2并抑制其与m6A修饰的靶转录物相互作用、诱导凋亡和分化的IGF2BP2抑制剂。

  • GC73441 structure
    GC73441EAPB 02303
    CAS: 1958290-51-1
    纯度: >99.00%

    EAPB 02303是一种微管破坏剂和抑制剂。

  • GC73452 structure
    GC73452CCT374705
    CAS: 2640647-90-9
    纯度: >99.00%

    CCT374705是一种口服活性BCL6抑制剂,在体外具有强效的抗增殖作用。